---
title: "BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 1.352 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285725090.md"
datetime: "2026-05-08T12:32:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285725090.md)
  - [en](https://longbridge.com/en/news/285725090.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285725090.md)
---

# BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 1.352 M

Revenue: As of FY2026 Q1, the actual value is USD 1.352 M.

EPS: As of FY2026 Q1, the actual value is USD -0.81.

EBIT: As of FY2026 Q1, the actual value is USD -3.612 M.

### First Quarter 2026 Financial Results

#### Segment Revenue

-   **CyPath®Lung Testing Revenue**: Increased approximately 114% to $361,000 in Q1 2026, compared to $169,000 in Q1 2025. Total Consolidated Revenue decreased approximately 27% to $1.4 million in Q1 2026, from $1.9 million for Q1 2025. This decline was primarily due to the discontinuation of certain unprofitable pathology services in March 2025 to focus on higher margin services, including CyPath®Lung testing. Net Revenue for Q1 2026 was $1,351,527, down from $1,853,597 in Q1 2025 .

#### Operational Metrics

-   **Operating Expenses**: Total operating expenses for Q1 2026 were $4,968,503, compared with $4,480,736 in Q1 2025 .
    -   **Direct Costs and Expenses**: $928,636 in Q1 2026, a 32% decrease from $1,367,860 in Q1 2025 .
    -   **Research and Development Expenses**: $349,707 in Q1 2026, a 5% decrease year-over-year from $367,386 in Q1 2025 .
    -   **Clinical Development Expenses**: Rose to $334,040 in Q1 2026, from $138,353 in Q1 2025 .
    -   **Selling, General and Administrative Expenses**: $3,241,602 in Q1 2026, up from $2,452,549 in Q1 2025 .
    -   **Depreciation and Amortization**: $114,518 in Q1 2026, compared to $154,588 in Q1 2025 .
-   **Loss from Operations**: -$3,616,976 in Q1 2026, compared to -$2,627,139 in Q1 2025 .
-   **Net Loss**: -$3,630,610 for Q1 2026, compared with -$2,660,417 for Q1 2025 .

#### Cash and Cash Equivalents

-   **Cash and Cash Equivalents**: As of March 31, 2026, cash and cash equivalents were $3,098,366, compared with $6,449,782 as of December 31, 2025 .

#### Unique Metrics

-   **CyPath®Lung Unit Sales**: Increased 146% year-over-year in Q1 2026 .
-   **Number of Physician Offices and Clinics Ordering CyPath®Lung**: Increased 69% from Q1 2025 to Q1 2026 .

#### Outlook / Guidance

The company anticipates accelerated growth throughout 2026, driven by commercial initiatives and increased awareness of CyPath®Lung’s benefits. Strategic priorities for the remainder of 2026 include scaling commercial execution, expanding into new geographic markets, and enhancing CyPath®Lung utilization through physician engagement. The company also plans to advance its pipeline of lung disease diagnostics by leveraging its platform .

### Related Stocks

- [BIAFW.US](https://longbridge.com/en/quote/BIAFW.US.md)

## Related News & Research

- [First Trust High Yield Opportunities 2027 Term Fund Declares its Monthly Common Share Distribution of $0.125 Per Share for June | FTHY Stock News](https://longbridge.com/en/news/287112918.md)
- [Prediction: This Will Be Micron's Stock Price at the End of 2027 (Hint: It's Well Over $1,000)](https://longbridge.com/en/news/287072976.md)
- [Prediction: These 4 Stocks Will Hit a $3 Trillion Valuation by the End of 2027](https://longbridge.com/en/news/287057166.md)
- [EnerSys Announces Dividend of $0.2625 per Share for the First Quarter of Fiscal Year 2027 | ENS Stock News](https://longbridge.com/en/news/287113840.md)
- [Doximity (DOCS) Is Down 27.0% After Softer 2027 Outlook And Higher AI Spend - What's Changed](https://longbridge.com/en/news/286669018.md)